Direct-Acting Vasodilators

被引:37
作者
Cohn, Jay N. [1 ]
McInnes, Gordon T. [2 ]
Shepherd, Alexander M. [3 ]
机构
[1] Univ Minnesota, Sch Med, Div Cardiovasc, Minneapolis, MN 55455 USA
[2] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland
[3] UT Hlth Sci Ctr, Grad Sch Biomed Sci, San Antonio, TX USA
关键词
HEART-FAILURE; SEVERE HYPERTENSION; HYDRALAZINE; MINOXIDIL; NITROPRUSSIDE; PHARMACOLOGY; PHENOTYPE; MECHANISM; NITRATES;
D O I
10.1111/j.1751-7176.2011.00507.x
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Key Points and Practical Recommendations Hydralazine and minoxidil act by dilating resistance arterioles, thus reducing peripheral resistance, with no dilating effect on the venous side of the circulation. There is a baroreflex-mediated venoconstriction, resulting in an increase in venous return to the heart, along with a direct catecholamine-mediated positive inotropic and chronotropic stimulation of the heart. Hydralazine therapy is usually combined with a sympathetic inhibitor to prevent expression of this reflex, as well as with a diuretic agent to prevent sodium retention caused by reduction in renal perfusion pressure. Hydralazine is indicated in the long-term therapy of essential hypertension, in the short-term therapy of pregnancy-induced hypertension and eclampsia, and in the therapy of hypertensive crisis. Adverse effects include the anticipated tachycardia, fluid retention, and headache, caused by the vasodilation, especially in the early days of therapy, but may frequently be prevented by the concomitant use of a beta-blocker. As with other drugs that are N-acetylated, there is a low risk of lupus-like syndrome with high doses and long-term use. Because of the severity of adverse effects with minoxidil, its usage is limited to persons with severe hypertension unresponsive to other treatments. Hirsutism, a common side effect of minoxidil, is particularly bothersome in women and reverses in a few months after discontinuation. Sodium nitroprusside is used in the intensive care setting to lower pressure in hypertensive crisis or to treat severe left ventricular failure, particularly valuable when elevated pressure or severe left ventricular failure threatens the patient's survival. Although nitrates have not achieved widespread use as antihypertensive agents, they are effective in producing sustained blood pressure (BP) reductions when added to other antihypertensive regimens. J Clin Hypertens (Greenwich). 2011; 13:690-692. (C)2011 Wiley Periodicals, Inc.
引用
收藏
页码:690 / 692
页数:3
相关论文
共 20 条
[1]   CLINICAL-PHARMACOLOGY OF POTASSIUM CHANNEL OPENERS [J].
ANDERSSON, KE .
PHARMACOLOGY & TOXICOLOGY, 1992, 70 (04) :244-254
[2]   NEED FOR BETA-BLOCKADE IN HYPERTENSION REDUCED WITH LONG-TERM MINOXIDIL [J].
BRUNNER, HR ;
JAEGER, P ;
FERGUSON, RK ;
JEQUIER, E ;
TURINI, G ;
GAVRAS, H .
BMJ-BRITISH MEDICAL JOURNAL, 1978, 2 (6134) :385-388
[3]   EFFECT OF MINOXIDIL ON BLOOD-PRESSURE AND HEMODYNAMICS IN SEVERE HYPERTENSION [J].
BRYAN, RK ;
HOOBLER, SW ;
ROSENZWEIG, J ;
WELLER, JM .
AMERICAN JOURNAL OF CARDIOLOGY, 1977, 39 (06) :796-801
[4]   DRUGS 5 YEARS LATER - NITROPRUSSIDE [J].
COHN, JN ;
BURKE, LP .
ANNALS OF INTERNAL MEDICINE, 1979, 91 (05) :752-757
[5]   PREVENTION OF TOLERANCE TO HEMODYNAMIC-EFFECTS OF NITRATES WITH CONCOMITANT USE OF HYDRALAZINE IN PATIENTS WITH CHRONIC HEART-FAILURE [J].
GOGIA, H ;
MEHRA, A ;
PARIKH, S ;
RAMAN, M ;
AJITUPPAL, J ;
JOHNSON, JV ;
ELKAYAM, U .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (07) :1575-1580
[6]   TREATMENT OF REFRACTORY HEART-FAILURE WITH INFUSION OF NITROPRUSSIDE [J].
GUIHA, NH ;
COHN, JN ;
MIKULIC, E ;
FRANCIOSA, JA ;
LIMAS, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (12) :587-592
[7]   SERIAL ELECTROCARDIOGRAPHIC CHANGES DURING LONG-TERM TREATMENT OF SEVERE HYPERTENSION WITH MINOXIDIL [J].
HALL, D ;
FROER, KL ;
RUDOLPH, W .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1980, 2 :S200-S205
[8]  
IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739
[9]   PHARMACOLOGY AND PHARMACOKINETICS OF MINOXIDIL [J].
LOWENTHAL, DT ;
AFFRIME, MB .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1980, 2 :S93-S106
[10]  
MEISHERI KD, 1988, J PHARMACOL EXP THER, V245, P751